Viewing Study NCT05494060

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:16 AM
Ignite Modification Date: 2026-02-20 @ 10:57 PM
Study NCT ID: NCT05494060
Status: RECRUITING
Last Update Posted: 2023-11-07
First Post: 2022-08-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma View
None Gastrointestinal Diseases View
None Stomach Cancer View
None Gastroesophageal-junction Cancer View
None Digestive System Diseases View
None Gastric Cancer View
None Gastrointestinal Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Penpulimab View
None Anlotinib View
None Capecitabine View
None Oxaliplatin View
None ctDNA View
None adjuvant therapy View